S&P Downgrades Valeant After Default Notice from Shareholder
Standard & Poor’s Ratings Services yesterday lowered Valeant Pharmaceuticals International Inc.’s corporate credit rating after a large holder called a default as a result of the Canadian drugmaker’s failure to file its annual report earlier this year, the Wall Street Journal reported today. The ratings agency, which notched Valeant down to B from B+, also lowered the company’s secured debt rating, to BB- from BB. Centerbridge Partners LP, a $25 billion private-equity and distressed debt investor, recently sent Valeant a notice of default, the Wall Street Journal reported on Tuesday. Valeant reiterated then that it remains on schedule to file the report by April 29, which would enable it to avoid a default. New York-based Centerbridge owns about $250 million in face value of Valeant’s $1 billion bond issue due 2023, some of the people said. Under Valeant debt covenants, holders of 25 percent of any single issuance of bonds under certain circumstances, such as untimely financial statements, can call a default.